In a company release, Accuray Inc. announced its CyberKnife radiotherapy platform, which delivers stereotactic radiosurgery to treat lesions in the brain, was supported by more than 2 decades of ...

SUNNYVALE, Calif., March 31, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (TN) showed ...

Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications SRS and FSRT – also referred to as ...

February 8, 2012 — Cyberknife radiosurgery to relieve trigeminal neuralgia refractory to medical management is a promising, viable alternative to more invasive treatment for this painful condition, ...

SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published ...

SUNNYVALE, Calif., July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15 th Congress of the International Stereotactic ...

ATLANTA, Oct. 5 – Treating benign tumors outside the brain with CyberKnife Frameless Radiosurgery resulted in significant improvement in symptoms and minimal toxicity, according to a study by ...

Its name is synonymous with treating brain, lung, liver and prostate cancer. But experts at Gibbs Cancer Center & Research Institute at Pelham are using it for so much more. The CyberKnife Robotic ...

Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis., March 26, 2024 /PRNewswire/ -- ...